Second interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Di ...
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...
Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
AstraZeneca (NASDAQ:AZN) shares gained in European trading on Thursday after the Anglo-Swedish drugmaker reported better-than-expected Q4 2024 results and addressed investor concerns over an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback